New breakthrough drug for leukaemia trialled at The Christie

Press/Media: Research

Description

A new drug being trialled at The Christie NHS Foundation Trust in Manchester could be a breakthrough for patients with a hard-to-treat form of leukaemia.

The drug, which is known as NX-5948, and so new it doesn’t have a name, is for the treatment of patients with CLL (chronic lymphocytic leukaemia) whose disease has come back after previous treatment or the cancer has stopped responding to treatment. CLL is a type of cancer of the blood and bone marrow. 

Period24 Apr 2024

Media coverage

1

Media coverage

  • TitleNew breakthrough drug for leukaemia trialled at The Christie
    Media name/outletThe Christie NHS Foundation Trust
    Media typeWeb
    Country/TerritoryUnited Kingdom
    Date24/04/24
    DescriptionA new drug being trialled at The Christie NHS Foundation Trust in Manchester could be a breakthrough for patients with a hard-to-treat form of leukaemia.

    The drug, which is known as NX-5948, and so new it doesn’t have a name, is for the treatment of patients with CLL (chronic lymphocytic leukaemia) whose disease has come back after previous treatment or the cancer has stopped responding to treatment. CLL is a type of cancer of the blood and bone marrow.
    URLhttps://www.christie.nhs.uk/about-us/news-at-the-christie/latest-news-stories/new-breakthrough-drug-for-leukaemia-trialled-at-the-christie
    PersonsEmma Searle